Prominence of Microbiota to Predict Fibrous Stenosis in Crohn's DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared fecal microbiota between Crohn's disease patients with intestinal fibrous stenosis and those without stenosis, using a single-center cross-sectional cohort in China. The goal was to see whether gut microbes could help predict which patients develop fibrous stenosis, a complication current clinical tools struggle to forecast.
How was it studied?
Fecal samples from 53 Crohn's disease patients (confirmed by MRI-based enterography for stenosis status) underwent shotgun metagenomic sequencing. The team compared microbial diversity, taxon abundance (order through species level), LEfSe biomarker analysis with ROC prediction accuracy, and KEGG and eggNOG functional pathway enrichment between the two groups.
What did they find?
Overall community diversity did not differ between groups, but 70 taxa showed significantly different abundance. Genus-level Bacteroides and Enterocloster predicted fibrous stenosis, while Actinobacteria, Bacilli, Lactobacillales, Streptococcaceae and Streptococcus predicted non-stenosis, with single-marker AUCs of 0.675 to 0.746 and a combined non-stenosis marker AUC of 0.730. Functionally, fibrous stenosis samples showed altered sphingolipid metabolism, lipoic acid metabolism, and neomycin/kanamycin/gentamicin biosynthesis pathways, plus differences across four eggNOG functional categories.
Why it matters
Even without overall diversity differences, specific fecal taxa and their metabolic functions tracked with fibrous stenosis, a complication that often forces endoscopic or surgical intervention once medications stop working. The findings point to fecal microbiota, particularly Bacteroides and Enterocloster abundance, as a potential non-invasive marker to flag Crohn's patients at risk for stricturing disease before it fully develops.